New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Where the cash went Twelve months to Sep 30, 2026

Free cash flow was −$32.6M: capital expenditures were more than operating cash flow. Cash fell by $32.6M. What is a cash flow statement?

Free cash flow
−$32.6M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$32.6M over the period
Where the cash went, in millions of dollars
Operating cash flow−32.6
Free cash flow−32.6
Change in cash−32.6
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow−$32M−$31M−$34M−$33M
Capex$1.2M$0.6M$0$0
Free cash flow−$30M−$30M−$33M−$33M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+8 more TTM periods

(45.52) (37.68) (36.11) (33.08)
Operating Cash Flow
(31.51) (30.65) (33.50) (32.64)
Investing cash flow
40.22 0.61 0.02 0.02
Financing cash flow
— — — —
Ending Cash
46.30 16.28 12.83 13.69

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 12, 2026